Default company panoramic image


Pangenx is a Personal Medicine company optimizing therapies based on individual genetics across drug R&D, clinical trials and care delivery sectors

  • Stage Full Product Ready
  • Industry Healthcare Services
  • Location Newton, MA, USA
  • Currency USD
  • Founded December 2009
  • Employees 14
  • Website

Company Summary

PanGenX’s mission is to enable the field of Personalized Medicine. PanGenX provides a real-time Business-to-Business (B2B) analytical solution for personalized medicine stakeholders—including national health systems, health plans, hospitals, and pharmaceutical companies—that intelligently leverages “Web 3.0” Linked Data (Semantic Technologies). Our solution combines the insights of renowned independent clinical pharmacologists alongside state-of-


  • Default avatar
    Tom Vasicek
    VP of Clinical Genetics

  • Default avatar
    Daniel Poscover

    As CEO, Dan drives the overall strategic vision for PanGenX. Dan is well known for his strategic insight in personalized medicine and provided consulting to leading therapeutic, diagnostic and health IT companies. Prior to founding PanGenX, Dan was a consultant at Third Rock Ventures, where he focused on establishing novel personalized medicine companies. Also, as a co-founder at Scientia, he led and managed a variety of functions for numerous li

  • Default avatar
    Eric Neumann

    Dr. Neumann, a graduate from MIT, is a recognized expert in Semantic Information Systems, and has worked on numerous information initiatives for the pharmaceutical and life sciences. He has founded and chaired the W3C Semantic Web Healthcare and Life Science Interest Group, which brings together many industry leaders to advance standards. Dr. Neumann is also the Executive Director and Founder of the Clinical Semantics Group, a consulting firm

  • Default avatar
    Alan Carter
    VP Bus Dev

  • Default avatar
    Barry Chaiken

    Barry P. Chaiken, MD, MPH, FHIMSS has over 20 years experience in healthcare information technology, patient safety, clinical transformation, and public health. He previously worked with the National Institutes of Health, U.K’s. National Health Service, McKesson, and BearingPoint. Chaiken served as a Board member (2006-2010), Board Liaison to HIMSS Europe (2006-2009), and Board Chair (2009-2010), and continues his involvement as a Fellow of the H

  • Default avatar
    Anne Marie Biernacki
    VP of Engineering

  • Default avatar
    David Neafus

    David, a driving force in the financial industry, has operated his own consulting firm providing executive services, specializing in interim executive management, IPOS, turnarounds, strategic analysis, and mergers and acquisitions, over the last 18 years. Previous clients include Stromedix, where as CFO, David helped the company complete its $500+ Million acquisition by Biogen. GlycoFi, where as CFO, David helped the company complete its $400+


  • Default avatar
    Jack Concannon